TABLE 3.
Number | Search strategies | Included trigger words | TPs | FPs | PPV | |||
---|---|---|---|---|---|---|---|---|
n | % | n | % | % | ||||
S1 | Keywords implying an ADR | Conjugations of | Drug‐induced | 20 | 10 | 5 | 1 | 80 |
Allergy | 17 | 8 | 80 | 21 | 18 | |||
Side effect | 21 | 10 | 10 | 3 | 68 | |||
Intolerance | 0 | 0 | 0 | 0 | n/a | |||
Reaction | 1 | 0 | 2 | 1 | 33 | |||
Toxicity | 13 | 6 | 1 | 0 | 93 | |||
S1 Total/overall ADRs found by keywords | 72 | 35 | 98 | 26 | 42 | |||
S2a | Prepositions followed closely b by a drug group c , a generic drug name, a drug brand, trade name or abbreviation a drug, or drug therapy d | Conjugations of | By | 16 | 8 | 19 | 5 | 41 |
With | 55 | 27 | 44 | 12 | 56 | |||
After | 12 | 6 | 67 | 18 | 15 | |||
Of | 31 | 15 | 62 | 16 | 33 | |||
On | 5 | 2 | 73 | 19 | 6 | |||
Since | 2 | 1 | 12 | 3 | 14 | |||
S2b | Abbreviations using the included prepositions | Conjugations of | As a result of/because of | 0 | 0 | 1 | 0 | 0 |
Based on | 3 | 1 | 0 | 0 | 100 | |||
As a consequence of | 4 | 2 | 1 | 0 | 80 | |||
S2 Total/overall ADRs found by a combination of predisposition and drug name | 128 | 62 | 278 | 74 | 31 | |||
S3 | Content of forms labelled a | Conjugations of | Allergies: | 0 | 0 | 0 | 0 | n/a |
Conjugations of | Anaphylaxis: | 0 | 0 | 0 | 0 | n/a | ||
S3 Total/overall ADRs found in labelled allergy and anaphylaxis forms | 0 | 0 | 0 | 0 | n/a | |||
S4 | Content of complication registration containing key field drug‐induced | … | … | 0 | 0 | 0 | 0 | n/a |
S5 | Content of ADR module | … | … | 6 | 3 | 0 | 0 | 100 |
S5 Total/overall ADRs found in ADR module | 6 | 3 | 0 | 0 | 100 | |||
Total ADRs identified | 206 | 100 | 377 | 100 | 35 |
Abbreviations: Adr, adverse drug reaction; FP, false positive; PPV, positive predicted value; TP, true positive.
Forms labelled allergy and anaphylaxis using free‐text entries were applied prior to the ADR module's introduction in 2015.
The maximum number of characters (ie, proximity between a preposition and drug name) was set at 16.
The drug group names were based on the Anatomical Therapeutic Chemical (ATC) therapeutic subgroup, pharmacological subgroup, chemical subgroup or chemical substance (ie, second to fifth levels of ATC main groups classified by WHO).
Examples are PPI (proton‐pump inhibitor), HCTZ (hydrochlorothiazide), FOLFOX (combination therapy of fluorouracil and oxaliplatin). A full list of abbreviations is provided in Table S2.